CFB
RIGL icon

Cullen/Frost Bankers’s Rigel Pharmaceuticals RIGL Stock Holding History

Cullen/Frost Bankers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.89K Sell
107
-1,175
-92% -$39.5K ﹤0.01% 1220
2025
Q4 		$54.9K Buy
1,282
+44
+4% +$1.66K ﹤0.01% 777
2025
Q3 		$35.1K Sell
1,238
-90
-7% -$2.69K ﹤0.01% 821
2025
Q2 		$24.9K Buy
1,328
+852
+179% +$16.2K ﹤0.01% 885
2025
Q1 		$8.56K Buy
476
+74
+18% +$1.5K ﹤0.01% 972
2024
Q4 		$6.76K Buy
+402
New +$7.71K ﹤0.01% 948

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cullen/Frost Bankers's RIGL Position: Q1 2026 in Review

Cullen/Frost Bankers reduced its Rigel Pharmaceuticals (RIGL) stake by 92% in Q1 2026, selling an estimated $39.5K and leaving 107 shares worth $2.89K. The position accounts for ﹤0.01% of the portfolio, ranked #1220.

Cullen/Frost Bankers first reported a position in RIGL in Q4 2024 and has held it in 6 quarters since. The position peaked at $54.9K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Cullen/Frost Bankers held 107 shares of Rigel Pharmaceuticals worth $2.89K as of Q1 2026.
  • Cullen/Frost Bankers sold 1,175 Rigel Pharmaceuticals shares in Q1 2026, an estimated $39.5K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q1 2026, its #1220 holding.
  • Cullen/Frost Bankers first reported a position in Rigel Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Cullen/Frost Bankers's Rigel Pharmaceuticals position peaked at $54.9K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.